

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: David A. Griffith :

Examiner: To Be Assigned

APPLICATION NO.: To Be Assigned :

FILING DATE: To Be Assigned

:Group Art Unit: To Be Assigned

TITLE: Cannabinoid Receptor Ligands and Uses Thereof :

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Date:

January 21, 2004

Respectfully submitted,

Arlene K. Musser

Arlene K. Musser

Attorney for Applicant(s)

Reg. No. 37,895

Pfizer Inc.
Patent Department, Box 8260-1611
Eastern Point Road
Groton, CT 06340
(860) 715-0871

EXPRESS MAIL NO. 50271824831US


INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC25512A		SERIAL NO. To Be Assigned		
		APPLICANT DAVID A. GRIFFITH				
		FILING DATE Herewith		GROUP To Be Assigned		
U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
M	US 3,865,824	02/11/75	Kobe, et al.			
M	US 3,910,907	10/07/75	O'Brien, et al.			
M	US 3,995,039	11/30/76	Rooney, et al.			
M	US 4,183,930	01/15/80	Cohen			
M	US 4,734,414	03/29/88	Kim			
M	US 4,767,858	08/30/88	Kim			
M	US 4,824,834	04/25/89	Fujii, et al.			
M	US 4,992,442	02/12/91	Tsujitani, et al.			
M	US 5,055,479	10/08/91	Takiguchi, et al.			
M	US 5,086,057	02/04/92	Takiguchi, et al.			
M	US 5,137,887	08/11/92	Hashimoto, et al.			
M	US 5,246,932	09/21/93	Caulkett, et al.			
M	US 5,270,311	12/14/93	Caulkett, et al.			
M	US 5,290,776	03/01/94	Caulkett, et al.			
M	US 5,356,894	10/18/94	Rodney, et al.			
M	US 5,380,714	01/10/98	Jones, et al.			
M	US 5,420,128	05/30/95	Kiyokawa, et al.			
M	US 5,571,813	11/05/96	Ruhter, et al.			
M	US 5,602,136	02/11/97	Ruhter, et al.			
M	US 5,602,137	02/11/97	Ruhter, et al.			
M	US 6,060,478	05/09/00	Gilligan, et al.			
M	US 6,124,289	09/26/00	He, et al.			

EXPRESS MAIL NO. 2027182483105

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC25512A		SERIAL NO. To Be Assigned			
		APPLICANT DAVID A. GRIFFITH					
		FILING DATE Herewith		GROUP To Be Assigned			
M	US 6,136,809	10/24/00	Gilligan, et al.				
M	US 6,191,131 B1	02/20/01	He, et al.				
M	US 6,194,410 B1	02/27/01	Bos, et al.				
M	US 6,313,124 B1	11/06/01	He, et al.				
M	US 6,358,950 B1	03/19/02	He, et al.				
M	US 6,372,743 B1	04/16/02	Darrow, et al.				
M	US 6,476,038 B1	11/05/02	Darrow, et al.				
M	US 6,509,338 B1	01/21/03	Olson, et al.				
M	US 2003/0008885 A1	01/09/03	He, et al.				
M	US 2003/0125330 A1	07/03/03	Gilligan				
FOREIGN PATENT DOCUMENTS							
DOCUMENT NUMBER		DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
M	EP 269 859 B2	10/18/95	Europe				
M	WO 01/54695 A1	08/02/03	PCT				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
M		Sato, Yasunobu, et al., "Studies on Cardiovascular Agents. 6. Synthesis and Coronary Vasodilating and Antihypertensive Activities of 1,2,4-Triazolo[1,5-a]pyrimidines Fused to Heterocyclic Systems," <u>J. Med. Chem.</u> , 23 , 927-937 (1980).					
M		Senga, Keitaro, et al., "Synthesis and Antischistosomal Activity of Certain Pyrazolo[1,5-a]pyrimidines," <u>J. Med. Chem.</u> , 24 , 610-613 (1981).					
M		Senga, Keitaro, et al., "Synthesis and Enzymic Activity of Various Substituted Pyrazolo[1,5-a]-1,3,5-triazines as Adenosine Cyclic 3',5'-Phosphate Phosphodiesterase Inhibitors," <u>J. Med. Chem.</u> , 25 , 243-249 (1982).					
M		He, Liqi, et al., "4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2,4-dichlorophenyl)-pyrazolo[1,5-a]-1,3,5-triazine: A Potent, Orally bioavailable CRF3 Receptor Antagonist," <u>J. Med. Chem.</u> , 43 , 449-456 (2000).					
M		Almansa, Carmen, et al., "Synthesis and SAR of a New Series of COX-2 Selective Inhibitors: Pyrazolo[1,5-a]pyrimidines," <u>J. Med. Chem.</u> , 44 , 350-361 (2001).					
EXAMINER		V. Balasubramanian		DATE CONSIDERED		9/16/05	

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 11th day of March, 2004.

By


(Signature of person mailing)
Tracy Mycroft

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: David A. Griffith :

APPLICATION NO.: 10/763,105 : Examiner: To be assigned

FILING DATE: January 21, 2004 : Group Art Unit: To be assigned

TITLE: Cannabinoid Receptor Ligands and Uses Thereof :

Hon. Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.


The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Date: March 11, 2004

Respectfully submitted,


Arlene K. Musser
Attorney for Applicant(s)
Reg. No. 37,895

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-0871

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>								ATTY. DOCKET NO. PC25512A				SERIAL NO. 10/763,105					
								APPLICANT David A. Griffith									
								FILING DATE January 21, 2004				GROUP Unknown					
U.S. PATENT DOCUMENTS																	
EXAMINER INITIAL		DOCUMENT NUMBER						DATE		NAME		CLASS		SUBCLASS		FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS																	
DOCUMENT NUMBER								DATE		COUNTRY		CLASS		SUBCLASS		TRANSLATION	
																YES NO	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)																	
M				C. Bellec et al., Can. J. Chem., 1981, Vol. 59, pp 2826-2832, "Deaminative Electrochemical Reduction of pyrazolo[1,5-a]pyrimidine-7-amines".													
M				A. Takamizawa et al., Chem. Pharm. Bull., 1965, Vol. 13, 10, pp 1207-1220, "Syntheses of Pyrazole Derivatives. XI." Acetylation Products of 7-Aminopyrazolo[1,5-a]pyrimidines. Supplement".													
M				Y. Sawaki et al., Bull. Chem. Soc. Jpn., 1981, Vol. 54, pp 793-799, "Mechanism of the Reaction of Nitriles with Alkaline Hydrogen Peroxide. Reactivity of Peroxycarboximide Acid and Application to Superoxide Ion Reaction".													
M				H. Beyer et al., 1960, pp 2209-2216, ' Zur Umsetzung von Ketonitrielen mit Hydrazinderivaten der Kohlensäure"													
M				J. Kobe et al., December 1974, Vol. 11, pp 991-996, "The Chemistry of 4-Hydrazino-7-phenylpyrazolo{1,5-a}-1,3,5-triazines".													
EXAMINER V. Balasubramanian DATE CONSIDERED 9/16/05																	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.																	

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 28th day of May, 2004.

By

(Signature of person mailing)

Tracy Mycroft

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: David A. Griffith :

APPLICATION NO.: 10/763,105

: Examiner: To be Assigned

FILING DATE: January 21, 2004

: Group Art Unit: To be Assigned

TITLE: Cannabinoid Receptor Ligands and Uses Thereof :

Hon. Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

A first Office Action on the merits has not been received; therefore, no fee for this Supplemental Information Disclosure Statement is required. In the event that an Office Action has been mailed, please charge the appropriate fee to Deposit Account No. 16-1445.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a).

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Respectfully submitted,

Date:

May 28, 2004

Arlene K. Musser

Arlene K. Musser

Attorney for Applicant(s)

Reg. No. 37,895

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-0871



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC25512A		SERIAL NO. 10/763,105		
		APPLICANT DAVID A. GRIFFITH				
		FILING DATE 1/21/04		GROUP Not Available		
U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
M	US 20010027193 A1	10/04/01	Achard, et al.			
M	US 20010053788 A1	12/20/01	Lange, et al.			
M	US 20020019383 A1	02/14/02	Achard, et al.			
M	US 20020019421 A1	02/14/02	Biberman, et al.			
M	US 20020035102 A1	03/21/02	Achard, et al.			
M	US 20020091114 A1	07/11/02	Plot-Grosjean, et al.			
M	US 20020119972 A1	08/29/02	Leftheris, et al.			
M	US 20020128302 A1	09/12/02	Maruani, et al.			
M	US 20020188007 A1	12/12/02	Barth, et al.			
M	US 20030003145 A1	01/02/03	Abramovici, et al.			
M	US 20030055033 A1	03/20/03	Achard, et al.			
M	US 20030114495 A1	06/19/03	Finke, et al.			
M	US 20030139386 A1	07/24/03	Cote, et al.			
M	US 20030199536 A1	10/23/03	Thomas, et al.			
M	US 20040077650 A1	4/22/04	Dow			
M	US 20040092520 A1	5/12/04	Griffith			
M	US 4,925,846	05/15/90	Deacon, et al.			
M	US 4,944,790	07/31/90	Moser, et al.			
M	US 5,134,142	07/28/92	Matsuo, et al.			
M	US 5,462,960	10/31/95	Barth, et al.			
M	US 5,596,106	01/21/97	Cullinan, et al.			
M	US 5,624,941	04/29/97	Barth, et al.			
M	US 5,744,491	04/28/98	Boigegrain, et al.			

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC25512A		SERIAL NO. 10/763,105			
		APPLICANT DAVID A. GRIFFITH					
		FILING DATE 1/21/04		GROUP Not Available			
M	US 5,744,493	04/28/98	Boigegrain, et al.				
M	US 5,747,524	05/05/98	Cullinan, et al.				
M	US 5,925,768	07/20/99	Barth, et al.				
M	US 6,028,084	02/22/00	Barth, et al.				
M	US 6,100,259	08/08/00	Xiang, et al.				
M	US 6,344,474 B1	02/05/02	Maruani, et al.				
M	US 6,355,631 B1	03/12/02	Bouchard, et al.				
M	US 6,432,984 B1	08/13/02	Barth, et al.				
M	US 6,476,060 B2	11/05/02	Lange, et al.				
M	US 6,479,479 B2	11/12/02	Achard, et al.				
M	US 6,509,367 B1	01/21/03	Martin, et al.				
M	US 6,518,264 B2	02/11/03	Achard, et al.				
M	US 6,566,356 B2	05/20/03	Achard, et al.				
FOREIGN PATENT DOCUMENTS							
DOCUMENT NUMBER		DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
M	CA 2,387,138 equiv. to WO 01/028557 A1	04/26/01	CA				
M	US 2003087933 equiv. to WO 01/58450 A2	08/16/01	PCT				
M	US 5051518 equiv. to EP 293,220 B1	8/31/94	EP				
M	US 6642258 equiv. to WO 01/24798 A1	04/12/01	PCT				
M	WO 00/15609 A1	05/23/00	PCT				X
M	WO 01/029007 A1	04/26/01	PCT				
M	WO 01/032629 A1	05/10/01	PCT				X
M	WO 01/032663 A2	05/10/01	PCT				X
M	WO 01/85092 A2	11/15/01	PCT				X
M	WO 02/076949 A1	10/03/02	PCT				

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC25512A		SERIAL NO. 10/763,105			
		APPLICANT DAVID A. GRIFFITH					
		FILING DATE 1/21/04		GROUP		Not Available	
WA ✓	WO 03/006007 A1	01/23/03	PCT				
UM ✓	WO 03/007887 A2	01/30/03	PCT				
WV ✓	WO 03/018060 A1	03/06/03	PCT				X
WV ✓	WO 03/020217 A2	03/13/03	PCT				
WV ✓	WO 03/020314 A1	03/13/03	PCT				X
WV ✓	WO 03/02664Z A1	04/03/03	PCT				
WV ✓	WO 03/026648 A1	04/03/03	PCT				
WV ✓	WO 03/027069 A1	04/03/03	PCT				
WV ✓	WO 03/027076 A2	04/03/03	PCT				
WV ✓	WO 03/027114 A1	04/03/03	PCT				
WV ✓	WO 03/040107 A1	05/15/03	PCT				
WV ✓	WO 03/051850 A1	06/26/03	PCT				
WV ✓	WO 03/051851 A1	06/26/03	PCT				
WV ✓	WO 03/075660 A1	09/18/03	PCT				
WV ✓	WO 03/077847 A2	09/25/03	PCT				
WV ✓	WO 03/078413 A1	09/25/03	PCT				
WV ✓	WO 03/082190 A2	10/09/03	PCT				
WV ✓	WO 03/082191 A2	10/09/03	PCT				
WV ✓	WO 03/082256 A2	10/09/03	PCT				X
WV ✓	WO 03/082833 A1	10/09/03	PCT				X
WV ✓	WO 03/084943 A2	10/16/03	PCT				X
WV ✓	WO 03/086288 A2	10/23/03	PCT				
WV ✓	WO 03/087037 A1	10/23/03	PCT				
WV ✓	WO 04/012617 A2	02/12/04	PCT				
WV ✓	WO 96/02248 A1	02/01/96	PCT				

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC25512A	SERIAL NO. 10/763,105
		APPLICANT DAVID A. GRIFFITH	
		FILING DATE 1/21/04	GROUP Not Available
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
W	✓	Tzavara, E.T., et al., "The CB1 Receptor Antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: Implications for Therapeutic Actions," <u>J Pharmacol</u> , 138 , 544-553 (2003).	
W	✓	Racz, I., et al., "A Critical Role for the Cannabinoid CB1 Receptors in Alcohol Dependence and Stress-Stimulated Ethanol Drinking," <u>J Neurosci</u> , 23 (6), 2453-2458 (2003).	
W	✓	Crocì, T., et al., "Role of Cannabinoid CB1 Receptors and Tumor Necrosis Factor- α in the gut and systemic anti-inflammatory activity of SR 141716 (Rimonabant) in rodents," <u>Brit J Pharmacol</u> , 140 , 115-122 (2003).	
W	✓	DaSilva, G.E., et al., "Potentiation of Penile Erection and Yawning Responses to Apomorphine by Cannabinoid Receptor Antagonists in Rats," <u>Neurosci Lett</u> , 349 , 49-52 (2003).	
W	✓	Wang, L., et al., "Endocannabinoid Signaling via Cannabinoid Receptor 1 is Involved in Ethanol Preference and its Age-Dependent Decline in Mice," <u>PNAS</u> , 100 (3), 1393-1398 (2003).	
W	✓	Ruii, S., et al., "Synthesis and Characterization of NESS 0327: A Novel Putative Antagonist of the CB1 Cannabinoid Receptor," <u>J Pharmacol Exp Therap</u> , 306 , 363-370 (2003).	
W	✓	Howlett, A.C., et al., "International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors," <u>Pharmacol Rev</u> , 54 , 161-202 (2002).	
W	✓	Gomez, R., et al., "A Peripheral Mechanism for CB1 Cannabinoid Receptor-Dependent Modulation of Feeding," <u>J. Neurosci</u> , 22 (21), 9612-9617 (2002).	
W	✓	Wiley, J.L., et al., "Novel Pyrazole Cannabinoids: Insights into CB1 Receptor Recognition and Activation," <u>J Pharmacol Exp Therap</u> , 296 (3), 1013-1022 (2001).	
W	✓	Lellemand, F., et al., "Effects of CB1 Cannabinoid Receptor Blockade on Ethanol Preference After Chronic Ethanol Administration," <u>Alcohol Clin Exp Res</u> , 25 (9), 1317-1323 (2001).	
W	✓	Pertwee, R.G., "Cannabinoids and the Gastrointestinal Tract," <u>Gut</u> , 48 , 859-867 (2001).	
W	✓	Pertwee, R.G., "Cannabinoid Receptor Ligands: Clinical and Neuropharmacological Considerations, Relevant to Future Drug Discovery and Development," <u>Exp. Opin. Invest. Drugs</u> , 9 (7), 1573-1571 (2000).	
W	✓	Hungund, B.L and B.S. Basavarajappa, "Are Anadamide and Cannabinoid Receptors involved in Ethanol Tolerance? A Review of the Evidence," <u>Alcohol & Alcoholism</u> , 35 (2) 126-133, (2000).	
W	✓	Freedland, C.S., et al., "Effects of SR141716A, a Central Cannabinoid Receptor Antagonist, on Food-maintained Responding," <u>Pharmacol Biochem Behav</u> , 67 , 265-270 (2000).	
W	✓	Lan, R., et al., "Structure-Activity Relationships of Pyrazole Derivatives as Cannabinoid Receptor Antagonists" <u>J. Med. Chem</u> , 42 , 769-776 (1999).	
W		Pertwee, R.G., "Pharmacology of Cannabinoid Receptor Ligands" <u>Curr Med Chem</u> , 6 , 635-664 (1999).	
W		Basavarajappa, B.S., et al., "Chronic Ethanol Administration Down-regulates Cannabinoid Receptors in Mouse Brain Synaptic Plasma Membrane," <u>Brain Res</u> , 793 , 212-218 (1998).	
W		Thomas, B.F., et al., "Comparative Receptor Binding Analyses of Cannabinoid Agonists and Antagonists," <u>J Pharmacol Exp Therap</u> , 285 , 285-292 (1998).	
W		Colombo, G., et al., "Appetite Suppression and Weight Loss after the Cannabinoid Antagonist SR141716," <u>Life Sci</u> , 63 , PL113-PL117 (1998);	
W		Simiand, J., et al., "SR141716, a CB1 Cannabinoid Receptor Antagonist, Selectively Reduces Sweet Food Intake in Marmoset," <u>Behav. Pharmacol.</u> , 9 , 179-181 (1998).	
W		Chaperon, F., et al., "Involvement of Central Cannabinoid (CB1) Receptors in the Establishment of Place Conditioning in Rats," <u>Psychopharmacology</u> , 135 , 324-332 (1998).	
W		Amone, M., et al., "Selective Inhibition of Sucrose and Ethanol Intake by SR141716, an Antagonist of Central Cannabinoid (CB1) Receptors," <u>Psychopharmacol</u> , 132 , 104-106 (1997).	

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC25512A	SERIAL NO. 10/763,105
		APPLICANT DAVID A. GRIFFITH	
		FILING DATE 1/21/04	GROUP Not Available

M	Savontaus, E., et al., "Anti-Obesity Effect of MPV-1743 A III, a Novel Imidazoline Derivative, in Genetic Obesity," <u>Eur J Pharmacol</u> , 328 , 207-215 (1997).
M	Sanudo-Pena, M.C., et al., "Endogenous Cannabinoids as an Aversive or Counter-rewarding System in the Rat," <u>Neurosci Lett</u> , 223 , 125-128 (1997).
M	Gifford, A.N., et al., "Electrically Evoked Acetylcholine Release from Hippocampal Slices is Inhibited by the Cannabinoid Receptor Agonist, WIN 55212-2 and is Potentiated by the Cannabinoid Antagonist, SR 141716A," <u>J Pharmacol Exp Ther</u> , 277 , 1431-1436 (1996).
M	Compton, D.R., et al., "In Vivo Characterization of a Specific Cannabinoid Receptor Antagonist (SR141716A); Inhibition of Delta-9-Tetrahydrocannabinol-Induced Responses and Apparent Agonist Activity," <u>J Pharmacol Exp Ther</u> , 277 , 586-594 (1996).
M	Mansbach, R.S., et al., "Effects of the Cannabinoid CB1 Receptor Antagonist SR141716A on the Behavior of Pigeons and Rats," <u>Psychopharmacology</u> , 124 , 315-322 (1996).
M	Lichtman, A.H., et al., "Delta-9-Tetrahydrocannabinol Impairs Spatial Memory through a Cannabinoid Receptor Mechanism," <u>Psychopharmacology</u> , 126 , 125-131 (1996).
M	Perio, A., et al., "Central Mediation of the Cannabinoid Cue: Activity of a Selective CB1 Antagonist, SR141716A," <u>Behavioral Pharmacology</u> , 7 , 65-71 (1996).
M	Rinaldi-Carmona, M., et al., "Biochemical and Pharmacological Characterization of SR141716A, The First Potent and Selective Brain Cannabinoid Receptor Antagonist," <u>Life Sci</u> , 56 , 1941-1947 (1995).
M	Pertwee, R., et al., "AM630, A Competitive Cannabinoid Receptor Antagonist," <u>Life Sci</u> , 56 , 1949-1955 (1995).
M	Rinaldi-Carmona, M., et al., "SR141716A, a Potent and Selective Antagonist of the Brain Cannabinoid Receptor," <u>FEBS Letters</u> , 350 , 240-244 (1994).
M	Dutta, A., et al., "The Synthesis and Pharmacological Evaluation of the Cannabinoid Antagonist SR 141716A," <u>Med. Chem. Rev</u> , 5 , 54-62 (1994).
M	Drummond, J., et al., "Evaluation and Synthesis of Aminohydroxyisoxazoles and Pyrazoles as Potential Glycine Agonists," <u>J. Med. Chem</u> , 32 , 2116-2128 (1989).
M	Murray, W., et al., "A Simple Regioselective Synthesis of Ethyl 1,5-Diarylpyrazole-3-carboxylates" <u>J. Heterocyclic Chem</u> , 26 , 1389 (1989).
H	Dewey, W.L. "Cannabinoid Pharmacology," <u>Pharmacological Reviews</u> , 38(2) m 151-178 (1986).
S	Tewari, R.S., et al., "1,3-Dipolar Cycloaddition and Nucleophilic Substitution Reactions of C-Acetyl and C-Ethoxycarbonyl Derivative of Hydrazidoyl Bromides" <u>Tetrahedron</u> , 39(1) 129-136 (1983).
B	Birkofer, L. and K. Richtzenhain, "Silyl-Derivate von Pyrazol, Isoxazol und 1,2,3-Triazol" <u>Chem. Ber.</u> 112 , 2829-2836 (1979).
M	Franke, H. et al., "Polare Cycloadditionen von elektronenreichen Mehrfach-bindungssystemen an 1,3,4-oxadiazolium-Salze: Synthese von 3aH-[1,3,4]Oxadiazolo[3,2-a]chinolinen" <u>Chem. Ber.</u> 112 , 3623-3636 (1979).
M	Sucrow, W., et al., "Bimolekulare Cyclisierung von 2-(1-Methylhydrazino)maleinsäure-dimethylester" <u>Chem. Ber.</u> 112 , 1712-1718 (1979).

EXAMINER	<i>V. Balasubramanian</i>	DATE CONSIDERED	9/16/08
----------	---------------------------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



IFW

Patent Application
Attorney Docket No. PC25512A

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 27th day of July, 2004.

By

(Signature of person mailing)
Tracy Mycroft

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: David A. Griffith :
APPLICATION NO.: 10/763,105 : Examiner: To be Assigned
FILING DATE: January 21, 2004 : Group Art Unit: 1614
TITLE: Cannabinoid Receptor Ligands and Uses Thereof :

Hon. Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

A first Office Action on the merits has not been received; therefore, no fee for this Supplemental Information Disclosure Statement is required. In the event that an Office Action has been mailed, please charge the appropriate fee to Deposit Account No. 16-1445.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a).

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Respectfully submitted,

Date: July 27, 2004

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-0871

Arlene K. Musser
Attorney for Applicant(s)
Reg. No. 37,895

APPLICANT **David A. Griffith**

FILING DATE January 21, 2004

GROUP	1614
-------	------

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
M	WO	03	0	9	5	4	5	5	11/20/03	International	C07D			
M	EP	1	3	5	4	8	8	4	10/22/03	European	C07D			
M	WO	02	0	5	3	5	6	5	7/11/02	International	C07D		X	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

			U.S. Patent Application Publication No. 2004/0072833, published April 15, 2004, equivalent to WO02053565.


EXAMINER

V. Balasubramanian

DATE CONSIDERED

9/16/08

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FW

Patent Application
Attorney Docket No. PC25512A

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 13th day of December, 2004.

By


(Signature of person mailing)

Erica L. Smith

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: David A. Griffith :
APPLICATION NO.: 10/763,105 : Examiner: To be Assigned
FILING DATE: January 21, 2004 : Group Art Unit: 1614
TITLE: Cannabinoid Receptor Ligands and Uses Thereof :

Hon. Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

A first Office Action on the merits has not been received; therefore, no fee for this Supplemental Information Disclosure Statement is required. In the event that an Office Action has been mailed, please charge the appropriate fee to Deposit Account No. 16-1445.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a).


It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Respectfully submitted,


Date:

12/13/04

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-0871




Arlene K. Musser
Attorney for Applicant(s)
Reg. No. 37,895



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				ATTY. DOCKET NO. PC25512A				SERIAL NO. 10/763,105					
				APPLICANT David A. Griffith									
				FILING DATE January 21, 2004				GROUP 1614					
U.S. PATENT DOCUMENTS													
EXAMINER INITIAL		DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
W W W		2004/0077650						4/22/04	Dow	514	242		
		2004/0092520						5/13/04	Griffith	514	242		
		2004/0122074						6/24/04	Dow, et al.	514	397		
FOREIGN PATENT DOCUMENTS													
DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
												YES	NO
EXAMINER <i>V. Balensubramanian</i> DATE CONSIDERED <i>9/16/05</i>													
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

Conforms with FORM PTO-FB-A820


INFORMATION DISCLOSURE



Patent Application
Attorney Docket No. PC25512A

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 27th day of January, 2005.

By


(Signature of person mailing)

Erica L. Smith

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: David A. Griffith :
APPLICATION NO.: 10/763,105 : Examiner: To be Assigned
FILING DATE: January 21, 2004 : Group Art Unit: 1614
TITLE: Cannabinoid Receptor Ligands and Uses Thereof :

Hon. Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

Under 37 C.F.R. 1.97(e)(1), I hereby certify that each item of information contained in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this statement.


The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

The Examiner is respectfully requested to indicate his or her consideration of the foregoing items by initialing, signing, and dating the accompanying PTO-FB-A820 and then returning a copy of the same to the undersigned. It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: January 24, 2005
Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-0871


Arlene K. Musser
Attorney for Applicant(s)
Reg. No. 37,895

(Use several sheets if necessary)

APPLICANT David A. Griffith

FILING DATE January 21, 2004

GROUP 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
M	WO	02	0	7	2	2	0	2	3/6/02	International	A61P	25/00		
M	WO	03	0	7	6	4	4	1	2/24/03	International	C07D	487/04		
M	WO	2004	0	2	2	0	5	4	9/5/03	International	A61K	31/415		
M	WO	9	8	0	3	5	1	0	7/23/97	International	C07D	487/04		

EXAMINER

V. Balasubramanian

DATE CONSIDERED

9/16/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.